Have a feature idea you'd love to see implemented?
Let us know!
ANIK Anika Therapeutics Inc
Price (delayed)
$24.99
Market cap
$369.77M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.07
Enterprise value
$332.74M
Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Anika Therapeutics partners with clinicians to understand what they need
Highlights
Anika Therapeutics's debt has decreased by 7% YoY and by 2.1% QoQ
The company's gross profit rose by 4.6% YoY
Anika Therapeutics's quick ratio has decreased by 15% YoY but it has increased by 4.5% from the previous quarter
ANIK's equity is down by 23% year-on-year
Key stats
What are the main financial stats of ANIK
Market
Valuations
Earnings
Shares outstanding
14.8M
Market cap
$369.77M
Enterprise value
$332.74M
Price to book (P/B)
1.76
Price to sales (P/S)
2.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.99
Revenue
$166.88M
EBIT
-$76.86M
EBITDA
-$63.51M
Free cash flow
$1.14M
Per share
Balance sheet
Liquidity
EPS
-$5.07
Free cash flow per share
$0.08
Book value per share
$14.18
Revenue per share
$11.25
TBVPS
$16.94
Total assets
$262.66M
Total liabilities
$52.32M
Debt
$25.79M
Equity
$210.34M
Working capital
$128.88M
Debt to equity
0.12
Current ratio
5.93
Quick ratio
3.7
Net debt/EBITDA
0.58
Margins
Efficiency
Dividend
EBITDA margin
-38.1%
Gross margin
61.9%
Net margin
-44.4%
Operating margin
-45.8%
Return on assets
-26.4%
Return on equity
-32.9%
Return on invested capital
-42%
Return on capital employed
-32.5%
Return on sales
-46.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ANIK stock price
How has the Anika Therapeutics stock price performed over time
Intraday
-1.15%
1 week
1.75%
1 month
-0.75%
1 year
33.14%
YTD
10.28%
QTD
1.17%
Financial performance
How have Anika Therapeutics's revenue and profit performed over time
Revenue
$166.88M
Gross profit
$103.27M
Operating income
-$76.36M
Net income
-$74.18M
Gross margin
61.9%
Net margin
-44.4%
Anika Therapeutics's operating income has plunged by 167% YoY but it has increased by 4.7% from the previous quarter
Anika Therapeutics's operating margin has plunged by 159% YoY but it has increased by 3.4% from the previous quarter
The company's gross profit rose by 4.6% YoY
The net income rose by 3.5% since the previous quarter
Growth
What is Anika Therapeutics's growth rate over time
Valuation
What is Anika Therapeutics stock price valuation
P/E
N/A
P/B
1.76
P/S
2.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.99
The company's EPS rose by 3.4% QoQ
ANIK's equity is down by 23% year-on-year
ANIK's price to book (P/B) is 17% more than its last 4 quarters average of 1.5 and 3.5% more than its 5-year quarterly average of 1.7
ANIK's P/S is 33% below its 5-year quarterly average of 3.3 but 11% above its last 4 quarters average of 2.0
The revenue has grown by 2.9% YoY
Efficiency
How efficient is Anika Therapeutics business performance
The ROIC has dropped by 173% year-on-year but it is up by 4.5% since the previous quarter
The company's return on sales has shrunk by 166% YoY but it rose by 3.4% QoQ
Anika Therapeutics's ROE has decreased by 3.5% from the previous quarter
The return on assets has declined by 2.3% since the previous quarter
Dividends
What is ANIK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ANIK.
Financial health
How did Anika Therapeutics financials performed over time
The total assets has decreased by 20% YoY
Anika Therapeutics's quick ratio has decreased by 15% YoY but it has increased by 4.5% from the previous quarter
Anika Therapeutics's debt is 88% lower than its equity
ANIK's equity is down by 23% year-on-year
The debt to equity is up by 20% year-on-year but it is down by 8% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.